Your Doctor, Your Insurer, Your Pharmacist — All the Same Company. That's a Problem.

A new bipartisan Senate bill wants to break up America's healthcare giants. It will cost some corporations dearly. It might save the rest of us a fortune.

Imagine walking into a car dealership to discover that the salesperson, the mechanic, the financing company, and the insurance provider are all owned by the same parent corporation. You might wonder: can I really get a decent deal? Now apply that same logic to your health insurance company, your pharmacy, your doctor's office, and the middleman who negotiates your drug prices. In America today, there's a very real chance they're all subsidiaries of the same conglomerate.

That's the reality the Break Up Big Medicine Act — introduced by the unlikely bipartisan pairing of Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) — is designed to dismantle. And while the bill will cause significant disruption for the investors and executives who've built these vast healthcare empires, the case for it is hard to ignore.

What vertical integration actually means for you

The term "vertical integration" sounds like something you'd hear in a business school lecture, but its real-world effects show up in your monthly premium, your copay at the pharmacy counter, and in the increasingly rushed seven-minute appointment you get with a doctor who's too overwhelmed to really listen.

Here's the basic idea: when a single corporation controls multiple links in the healthcare supply chain, like a health insurer and a pharmacy benefit manager (PBM) and a network of physician practices, it gains enormous power to steer money to its own affiliates, obscure how prices are set, and squeeze out independent competitors who can't match their scale.

A PBM, for instance, sits between your insurer and your pharmacy, ostensibly negotiating lower drug prices. But when the PBM and the insurer are the same company, or when the PBM owns the pharmacy filling your prescriptions, the "negotiation" starts to look less like a check on costs and more like a shell game where the money just moves between corporate pockets.

Nearly 80 percent of physicians in the United States now work for a corporate parent rather than an independent practice. That shift has real consequences for care: corporate ownership is associated with higher costs, more billing, and, in many studies, worse outcomes. When your doctor's employer has a financial interest in sending you to a specific specialist, a specific hospital, or a specific pharmacy under the same corporate umbrella, the conflict of interest is baked right into your care.

What the bill would actually do

The Break Up Big Medicine Act takes a structural approach: rather than trying to regulate the behavior of these conglomerates (a notoriously difficult task), it would simply make the most problematic ownership combinations illegal.

Key provisions include:

• Prohibits any company from owning both a medical provider (or management services organization) and a health insurer or PBM

• Prohibits common ownership of a drug or medical device wholesaler and a medical provider

• Requires companies currently in violation to divest within one year of the bill's enactment

• Creates automatic financial penalties — including disgorgement of profits — for non-compliance

• Empowers the FTC, DOJ, state attorneys general, and private parties to bring enforcement actions

This kind of structural separation isn't new. We've done it before in banking and in railroads precisely because we know that allowing one entity to control every node in a critical system was a recipe for abuse. Healthcare, which touches every American and accounts for nearly a fifth of the U.S. economy, deserves at least the same level of scrutiny.

Yes, it will disrupt big business — and that's the point

Let's be honest about the disruption this bill would cause. The companies in its crosshairs have spent years assembling physician networks and management structures specifically designed to thread the needle on state corporate practice rules and they would face enormous upheaval. Divestitures are expensive and complicated. Investors who bet on integrated healthcare platforms would take real losses.

That disruption is a feature, not a bug. The consolidation that produced these giants didn't happen because it was good for patients. It happened because it was enormously profitable for shareholders. Every acquisition, every merger, every management services organization layered on top of a physician practice was a bet that controlling more of the supply chain would mean more pricing power, more revenue, and more ability to extract money from a system that patients and taxpayers have no real choice but to use.

The bill's bipartisan sponsorship is meaningful here. This isn't a left-wing attack on capitalism — it's a recognition, shared across the political spectrum, that the current structure of American healthcare creates perverse incentives that harm ordinary people regardless of their politics. Senator Hawley is not exactly known for socialist sympathies. When a Republican from Missouri and a Democrat from Massachusetts agree that an industry needs to be structurally separated, that's worth taking seriously.

"Working Americans deserve better. This bipartisan legislation is a massive step towards making healthcare affordable for every American." — Sen. Josh Hawley (R-MO)

Transparency begins with separation

One of the least-discussed costs of vertical integration in healthcare is what it does to transparency. When the same company that insures you also runs the PBM deciding which drugs are covered and at what price, and also owns the pharmacy filling your prescription, it becomes nearly impossible for anyone to understand why prices are what they are.

Cost-shifting is way too easy when you control multiple entities in the chain. Profits can be booked wherever the tax or regulatory environment is most favorable. Losses can be attributed to one arm of the business while another arm quietly reaps the benefit. Patients see only the end result: a bill that seems disconnected from any rational calculation of what their care actually costs to provide.

Structural separation won't solve all of healthcare's opacity problems, but it's a place to start. You cannot have meaningful price transparency in a system where the payer, the price-setter, and the provider are all the same company with aligned financial interests.

The momentum is building

Even if the bill doesn't pass in its current form, it still reflects a direction that investors and healthcare executives better watch. Arkansas has already led the way by prohibiting PBMs from owning pharmacies. California, Massachusetts, and Oregon have enacted structural guardrails on healthcare ownership. The federal proposal builds on state-level momentum and signals that bipartisan consensus on structural remedies is within reach. So refreshing!

For patients — which is to say, for all of us! — that momentum can't build fast enough. The system as currently constructed is one where the house always wins. Breaking that up isn't radical. It's just common sense. If you agree, there is a letter of support here, or you can call the Congressional switchboard at 202-224-3121 and talk with staffers or your representative.